Home › Blood Disorders › Wisconsin › Milwaukee
Blood Disorders clinical trials in Milwaukee, WI
4 studies for Blood Disorders are looking for participants at sites in and around Milwaukee (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Versiti Wisconsin, Inc, Milwaukee
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- Versiti Wisconsin, Inc, Milwaukee
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Froedtert & Medical College of Wisconsin, Milwaukee
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Comprehensive Center for Bleeding Disorders, Milwaukee
About Blood Disorders
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
More about Blood Disorders on MedlinePlus
Blood Disorders trials in other cities
- Houston, TX11 studies
- Atlanta, GA11 studies
- Boston, MA10 studies
- Los Angeles, CA10 studies
- New York City, NY9 studies
- The Bronx, NY8 studies
- Durham, NC7 studies
- Nashville, TN7 studies
- Mountain View, CA7 studies
- San Diego, CA6 studies
- Seattle, WA6 studies
- Indianapolis, IN5 studies
Other studies in Milwaukee
- Cancer (all types)24 studies
- Multiple Myeloma23 studies
- Breast Cancer22 studies
- Non-Small Cell Lung Cancer21 studies
- Lung Cancer21 studies
- Non-Hodgkin Lymphoma19 studies
- Follicular Lymphoma19 studies
- Prostate Cancer19 studies
- Acute Myeloid Leukemia18 studies
- Pancreatic Cancer18 studies
- Ovarian Cancer17 studies
- Diffuse Large B-Cell Lymphoma17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.